We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice.
- Authors
Haynes, Lia M.; Caidi, Hayat; Radu, Gertrud U.; Congrong Miao; Harcourt, Jennifer L.; Tripp, Ralph A.; Anderson, Larry J.
- Abstract
Because the G protein of respiratory syncytial virus (RSV) has a CX3C chemokine motif that has been associated with the ability of RSV G protein to modulate the virus-induced host immune response, we examined whether therapeutic treatment with an anti-RSV G monoclonal antibody (mAb), 131-2G, that blocks the CX3Cassociated activity of RSV G protein might decrease the pulmonary inflammation associated with infection in BALB/c mice. The results show that treatment with mAb 131-2G on day 3 after RSV infection reduces both inflammation and RSV titer in the lungs. Later administration of anti-RSV G mAb (day 5 after RSV infection) effectively reduced the viral titer but had a minimal effect on pulmonary inflammation. This study suggests that an anti-RSV G mAb might be an effective antiviral, either alone or in combination with anti-RSV F protein neutralizing antibodies, for decreasing the virus-induced host response to infection and improve treatment outcome.
- Subjects
ANTIVIRAL agents; MONOCLONAL antibody probes; MONOCLONAL antibodies; ANTI-inflammatory agents; PATHOLOGY; VIRUSES
- Publication
Journal of Infectious Diseases, 2009, Vol 200, Issue 3, p439
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1086/600108